Anicetti Vincent R 4
4 · Coherus BioSciences, Inc. · Filed Jan 21, 2021
Insider Transaction Report
Form 4
Anicetti Vincent R
Chief, Quality & Compliance
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2021-01-19−2,500→ 2,488 totalExercise: $2.50Exp: 2024-06-30→ Common Stock (2,500 underlying) - Exercise/Conversion
Common Stock
2021-01-19$2.50/sh+2,500$6,251→ 62,239 total - Sale
Common Stock
2021-01-19$17.94/sh−2,500$44,852→ 59,739 total
Footnotes (4)
- [F1]Includes 52,083 restricted stock units.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- [F3]The transaction was executed in multiple trades in prices ranging from $17.76 to $18.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F4]All of the shares underlying this option are vested and exercisable as of the date hereof.